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A large number of studies have indicated that specific immune reactivity plays a crucial role in the control of malignant melanoma. In
this context, expression of MHC I, MHC II and B7 molecules by melanoma cells is seen as relevant for the immune response against
the tumour. For a better understanding of the biological relevance of MHC II and B7 expression by tumour cells in metastatic
melanoma, we studied the expression of these molecules in melanoma metastases in relation to the inflammatory response,
regression of the tumour and survival from 27 patients treated with biochemotherapy (30mgm
 2 Cisplatin and 250mgm
 2
decarbazine (dimethyl-triazene-imidazole-carboxamide, DTIC) on days 1–3 i.v., and 10
7IU IFN-a2b 3 days a week s.c., q. 28d). In 19
out of 27 lesions studied, we found expression of MHC II by the tumour cells, while only in one out of 11 tumour biopsies obtained
from untreated metastatic melanoma patients, MHC II expression was detected. Expression of B7.1 and B7.2 by tumour cells was
found in nine out of 24 and 19 out of 24 lesions, respectively. In all cases where B7.1 expression was found, expression of B7.2 by the
tumour cells was also seen. In general, no or only few inflammatory cells positive for B7 were found. Expression of MHC II by tumour
cells was positively correlated with the presence of tumour-infiltrating lymphocytes, regression of the lesion, and with time to
progression (TTP) and overall survival (OS) of the patient. However, no significant correlation between B7.1 or B7.2 expression and
regression of the tumour, TTP or OS was found. In light of other recent findings, these data altogether do support a role as biomarker
for MHC II expression by tumour cells; however, its exact immunological pathomechanism(s) remain to be established.
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Many studies have indicated that the immune system is capable of
controlling tumour growth in cancer patients, especially in
melanoma patients. Supportive findings comprise the occurrence
of spontaneous regressions in primary melanomas (McGovern,
1975; Kang et al, 1993), the prognostic relevance of the presence of
an inflammatory infiltrate in melanomas (Clemente et al, 1996;
Mihm et al, 1996), the selective reactivity of tumour-infiltrating
lymphocytes (TIL) against autologous tumour cells in 50% of
patients with metastatic melanoma (Castelli et al, 1997), and the
occurrence of objective responses in cancer patients following
immune-modulating treatment (Mukherji and Chakraborty, 1995;
Davis, 2000). From studies in animal tumour models and some
clinical observations, it has been shown that specific T lympho-
cytes fulfil a crucial role in the immunological control of tumour
growth (Castelli et al, 1997; Coulie et al, 1999; Yamshchikov et al,
2001). For T-cell activation and recognition of tumour cells by T
cells, antigen presentation in the context of MHC molecules is
required. The specific trigger for CD8+ and CD4+ T cells consists
of antigenic peptides complexed with MHC class I molecules or
MHC class II molecules, respectively. Expression of these antigens
by tumour cells is therefore considered relevant for the
immunological control of tumour growth. MHC I is normally
expressed by all nucleated cells. Data on the expression of MHC I
by tumour cells are consistent in that expression of these
molecules appears to be crucial for effective immune recognition
and consequently for immunological control of tumour growth.
Loss of MHC I expression is considered as one of the major
immune escape mechanisms exploited by tumour cells (Ruiter et al,
1982; Marincola et al, 1992; Rees and Mian, 1999; Algarra et al,
2000).
MHC II is normally not expressed by nonprofessional antigen-
presenting cells (APC). Data on the relevance of MHC II expression
by tumour cells for immunological control of tumour growth is, in
contrast to data on MHC I, not consistent. Melanocytes in normal
skin and common nevi are negative for MHC class II (Guerry et al,
1987; Ruiter et al, 1991), while MHC class II expression on
melanocytes does appear with neoplastic transformation (Guerry
et al, 1987; Ruiter et al, 1991) and may increase with increasing
malignancy or lesion thickness (Bro ¨cker et al, 1984; Becker et al,
1993). IFN-g induces MHC class II expression in melanoma cells as
well as in melanocytes (Guerry et al, 1987). In a number of mouse
tumour models, tumour cells transfected with MHC class II show
an increased immunogenicity compared to the parental cell line.
These cell lines also show CD4+ T cell stimulation in vitro.I ti s
hypothesised that the transfected tumour cells act as direct APC to
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www.bjcancer.comCD4+ cells, presenting endogenous tumour antigens (Chen et al,
1994; Pulaski and Ostrand-Rosenberg, 1998; Ostrand-Rosenberg
et al, 1999). In human primary melanoma, however, expression of
MHC class II by tumour cells is associated with an unfavourable
prognosis (van Duinen et al, 1988; Ruiter et al, 1991). In addition,
Becker et al (1993) reported that autologous melanoma cell lines
render CD4+ T cells unresponsive to subsequent stimulation in an
MHC class II restricted manner. This effect could be abrogated by
transfection of the melanoma cells with the costimulatory molecule
B7 (Becker et al, 1993). In summary, while studies in some animal
tumour models suggest that MHC II expression by tumour cells
increases the immunogenicity of the tumour, data on human
tumour cells suggest that MHC II expression might reduce the
immunogenicity of the tumour in patients with melanoma
metastases.
In this paper, we address the relevance of expression of MHC II
and the costimulatory molecules B7.1 and B7.2 in relation to
response to treatment with biochemotherapy.
MATERIALS AND METHODS
Patient data
The present study describes 27 patients (18 males and nine
females) with metastatic malignant melanoma, 15 with regional
disease and 12 with resectable systemic disease. The median age
was 58 (range 34–71) years and their Karnofsky status was 70 or
more. Recurrences were cytologically verified by fine-needle
aspirates before treatment was started. One metastasis from each
patient was studied. In patients with systemic disease, easily
resectable metastases were chosen. In patients with regional
disease, non-necrotic biopsies were randomly chosen by the
pathologist. In addition, tumour biopsies obtained from 11
untreated metastatic melanoma patients (nine males, two females)
were studied for MHC II expression. All these patients had regional
disease and a median age of 57 (range 39–79) years. Recurrences
were cytologically verified by fine-needle aspirates. One metastasis
from each patient was studied.
The study was approved by the ethical committee at the
University Hospital of Linko ¨ping, Sweden.
Pretreatment investigations and treatment schedule
Pretreatment investigations were as described previously
(Ha ˚kansson et al, 2001). Treatment consisted of 30mgm
 2
cisplatin (cis-diamine-dichloro-platinum) and 250mgm
 2 dacar-
bazine (dimethyl-triazene-imidazole-carboxamide, DTIC) on days
1–3 i.v., and 10
7IU IFN-a2b 3 days a week s.c. The duration of one
cycle was 28 days.
Preparation of tumour biopsies and immunological
staining of tissue sections
Biopsies from the resected metastases were immediately snap
frozen and stored at  701C until further use. Tissue sections, 6–
7mm thick, were fixed with phosphate-buffered 4% paraformalde-
hyde, pH 7.4 (Riedel-de Haen Ag, Seelze, Germany) supplemented
with 5.4gl
 1 of glucose for 5min and then washed three times in
Hanks’ balanced salt solution (BSS, Gibco, Paisley, UK), supple-
mented with 0.01 M Hepes solution before staining. For detection
of the expression of MHC antigens, B7.1, B7.2 and the presence of
T-cell subsets, the following monoclonal antibodies were used:
anti-HLA, Stockholm, Sweden, DR for MHC II (0.5mgml
 1, clone
L243; Becton Dickinson), anti-HLA-ABC for MHC I (0.57mgml
 1,
clone W6/32; Dakopatts, Oxon, UK), anti-B7.1 (20mgml
 1, clone
37711.11; R&D systems), anti-B7.2 (20mgml
 1, clone 37301.11;
R&D systems), anti-CD3 (7.5mgml
 1, clone UCHT1: Dako), leu-3a
for CD4 (1mgml
 1; Becton Dickinson) and Leu-2a for CD8
(0.25mgml
 1; Becton Dickinson). Sections for T-cell subsets were
blocked with normal rabbit serum before the first staining.
Sections for MHC I and MHC II were blocked with normal goat
serum and sections for B7.1 and B7.2 with 10% AB serum. Tissue
sections were then incubated with primary antibodies for 30min
or overnight (B7.1 and B7.2) at room temperature. Mouse IgG1
(Dakopatts, Sweden) was used as a negative control for the subsets
of inflammatory cells and the B7 antibodies. Mouse IgG (Sigma,
Stockholm, Sweden) was used as a negative control for the major
histocompatibility antigens. After the slides were washed in BSS-
saponin, biotinylated rabbit-anti-mouse immunoglobulin was
added at a 1:100 dilution in BSS-saponin for anti-CD3, anti-CD4
and anti-CD8. They were then incubated with peroxidase-labelled
streptavidin (P0397, DAKO, Stockholm, Sweden) at a 1:100
dilution in BSS-saponin for 30min. DAB (3,30-diaminobenzidine,
D-5637, Sigma, Stockholm, Sweden) was used as a substrate.
Sections stained for MHC I and MHC II were washed in BSS-
saponin; then, goat-anti-mouse immunoglobulin was added at a
1:25 dilution in BSS-saponin and left to incubate for 30min in a
moist chamber. The slides were again washed in BSS-saponin, and
mouse APAAP complex diluted at 1:25 in BSS-saponin was added
and incubated for 30min. For B7.1 and B7.2, the Envision system
was used as the second step (DAKO, Stockholm, Sweden). All
antibody solutions contained 2% normal blood donor AB serum.
After washes in BSS-saponin and TBS, the Fast-red substrate
supplemented with levamisole to block endogenous alkaline
phosphatase was added to the sections (MHC and B7) and left to
incubate for 20min at room temperature. The slides were then
washed in TBS, pH 7.6, counterstained in Mayer’s haematoxylin
for 15min and mounted in Glycergel (Dakopatts, Sweden).
Evaluation of tumour regression and histopathological
criteria
The occurrence of tumour regression was evaluated by histopath-
ological examination of tumour biopsies based on the description
of regressive changes in malignant melanoma as previously
described (McGovern, 1975; Kang et al, 1993; Ha ˚kansson et al,
1996, 1998). The following criteria of tumour regression were used
in this study: (1) low and variable density of tumour cells,
particularly variation in density within the same tumour nodule;
(2) disorganisation of the architecture of the tumour with nests of
remaining tumour cells surrounded by stromal tissue and (3)
fibrosis. The mononuclear infiltrate was not used as a criterion of
histopathological tumour regression in this study. The regressive
changes were scored on control sections not stained for mono-
nuclear cells. The signs of regression vary from no signs to almost
complete destruction with only a few tumour cells present. The
degree of tumour regression was scored semiquantitatively as less
than 10%, comprising 10–25, 25–50, 50–75 or 75–100% of the
section area. A score of 425% was generally considered significant
unless otherwise stated. The scoring was performed independently
by two observers (MRB, BG) and consensus was reached for all
scorings.
Statistical analysis
Survival curves were plotted using the Kaplan–Meier method.
Differences in clinical response in terms of time to progression and
OS between patients showing differences in expression of MHC II
or B7 by the tumour or differences in regressive changes in the
tumour were analysed using the log rank test. A two-sided Fisher’s
exact test was used to analyse whether or not an increased level of
MHC II expression coincided with an increased level of
histological regression. Calculations of significance were per-
formed using Graph Pad Prism version 3.02 for Windows (Graph
Pad Software, San Diego, CA, USA).
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MHC I and MHC II expression in metastatic lesions from
treated and untreated melanoma patients
The expression of MHC classes I and II was studied in 27 lesions
from biochemotherapy-treated patients by immunohistochemical
analysis. All lesions were homogeneously positive for MHC I. In
contrast, a heterogeneous expression of MHC II was found
between and within lesions. In eight out of these 27 lesions, the
tumour cells were negative for MHC II, while in the remaining 19
lesions, 10 to more than 75% of the tumour cells were positive for
MHC II (Figure 1A). In contrast, in 11 tumour biopsies derived
from untreated patients, only in one out of the 11 MHC II
expression was detected in approximately 75% of the tumour cells.
In all cases, MHC II expression of the tumour cells was associated
with a pronounced presence of TIL as exemplified in Figure 2A and
B. In all cases, these TIL consisted of CD4+ as well as CD8+ cells.
There was some heterogeneity in the relative occurrence of these
subpopulations, but this heterogeneity could not be linked to
whether or not adjacent tumour cells were positive for MHC II.
In all cases, the majority of inflammatory cells were MHC II-
positive.
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Figure 1 Distribution of MHC II (A) and B7 (B) expression over the lesions studied.
AB
CD
Figure 2 Expression of MHC II (A: red-stained cells, black arrows indicating positive tumour cells and white arrows indicating positive inflammatory cells)
and presence of CD3+ cells (B: brown-stained cells; the brown staining is not melanin) in corresponding areas of a metastatic lesion. Expression of B7.1 (C:
black arrows indicating positive-staining tumour cells and white arrows indicating negative inflammatory cells) and B7.2 (D: black arrows indicating positive
tumour cells and white arrows indicating positive inflammatory cells) in corresponding areas of a metastatic lesion (red-stained cells).
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patients
Also for B7, heterogeneous expression between and within lesions
was found. Out of 24 lesions studied for B7.1 and B7.2 expression,
15 were negative for B7.1 and five for B7.2 (Figure 1B). In most
cases where B7 expression was detected, the staining intensity
of the tumour cells was weak as compared to the staining intensity of
inflammatory cells when positive (Figure 2C). For B7.1 in none of
the 24 lesions, positive-staining inflammatory cells were observed.
In contrast, for B7.2 in 17 out of 24 lesions, positive staining of
inflammatory cells was seen (Figure 2C and D). In general,
however, only a limited fraction of the inflammatory cells were
positive for B7.2. In all lesions where B7.1 positive tumour cells
were found, positive staining for B7.2 was also found. In Figure 3
the relative distribution of B7.1 and B7.2 positive tumours, that is
more than 10% of the tumour cells positive, in relation to the
expression of MHC II by tumour cells is shown. Although it
seems that B7.1 expression is found more frequently in tumours
that are significantly positive for MHC II, that is more than 25% of
the tumour cells positive for MHC II, no specific relation between
MHC II expression and B7.1 or B7.2 expression could be discerned.
Relation between MHC II and B7 expression by tumour
cells and the occurrence of histological regression in
metastatic lesions of melanoma patients
Histological regression of tumour lesions was scored according to
criteria as published before (McGovern, 1975; Kang et al, 1993;
Ha ˚kansson et al, 1996, 1998) and as specified under Materials and
Methods. We plotted the extent of histological regression against
the percentage of MHC II-positive tumour cells found in each
lesion (Figure 4A). In 18 out of 27 lesions studied, regressive
changes were observed. Out of these 18, 10 were significantly
positive for MHC II, that is more than 25% of the tumour cells,
while in the remaining nine lesions that showed no significant
regressive changes, that is less than 25% of the section area, only in
one out of nine lesions MHC II expression in more than 25% of the
tumour cells was detected. This difference was statistically
significant (P¼0.042; two-sided Fisher’s exact test).
Similar to MHC II, we plotted the extent of histological
regression against the percentage of B7-positive tumour cells
found in each lesion (Figure 4B and C). There was, however, no
apparent relation between the occurrence of regressive changes
and B7 expression by the tumour cells.
Relevance of MHC II and B7 expression by tumour cells to
clinical response parameters
In order to establish whether or not expression of MHC II and or
B7 by tumour cells might be of clinical relevance, we performed
survival analysis on patients in relation to the extent to which their
tumour expressed MHC II or B7. For TTP as well as OS, there was a
significant trend for increased survival in relation to increased
expression of MHC II by the tumour (P¼0.034 and 0.043,
respectively; log rank test for trend). The use of a cutoff point of
25% of the tumour cells positive for MHC II results in a significant
difference in TTP and OS for the two resulting patient groups
(P¼0.034 and 0.032, respectively; Figure 5).
A similar approach was used for the relation between B7
expression by the tumour and TTP and OS of the patients. No
significant relation between B7 expression by the tumour and TTP
or OS was found (Figure 6).
DISCUSSION
Metastatic malignant melanoma is, despite various treatment
strategies, still associated with a poor prognosis. In other studies,
we have demonstrated that treatment with IFNa or IFNa in
combination with cisplatin and DTIC results in early (incomplete)
regression of metastases (Ha ˚kansson et al, 1996, 2001). These
responses showed a strong correlation with the amount of tumour-
infiltrating CD4+ lymphocytes present before treatment. However,
objective remission following IFNa-based treatment is still only
15% (Legha, 1997). These observations suggest that an initial
effective antitumour immune response is initiated following
treatment, but that shortly thereafter immunological resistance
occurs (Ha ˚kansson et al, 1999, 2001).
Given the apparent important role of CD4+ cells in the
induction of an effective immune response to the tumour, we
studied the expression of MHC II and B7 in melanoma metastases
of patients treated with IFNa, cisplatin and DTIC, in relation to the
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Figure 4 Relation between the extent of regression and expression of MHC II (A), B7.1 (B) and B7.2 (C).
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MHC II expression.
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the patients. In 19 out of 27 lesions studied, we found expression of
MHC II by the tumour cells. In contrast, in 11 tumour biopsies
obtained from metastatic melanoma patients before treatment,
only in one lesion MHC II expression by the tumour cells was seen.
These findings suggest a treatment-related expression of MHC II
by the tumour. This is further supported by the findings in three
fine-needle aspirate biopsies derived from three patients before
treatment (data not shown). In none of the three aspirates positive
staining of the tumour cells for MHC II was obtained, while in two
of the three corresponding post-treatment tumour biopsies MHC
II-positive tumour cells were detected (25–50 and 75–100%,
respectively). As also found by others (Bro ¨cker et al, 1984, 1988;
Guerry et al, 1987; Hersey and Jamal, 1990), we found a close
correlation between MHC II expression and presence of TIL. There
was also a positive correlation between MHC II expression by
tumour cells and regression of the lesion. MHC II expression was
also positively correlated with TTP and OS of the patients. Patients
whose tumours showed MHC II-positive staining of more than
25% of the tumour cells had a significant longer TTP and OS
survival than those whose tumour was negative or only limited
positive (less than 25% of the tumour cells) for MHC II. In this
study, MHC II expression on tumour cells thus represents a
biomarker for response. This expression of MHC II by tumour
cells might be of particular importance with regard to the
observation that the occurrence of CD4+ lymphocytes before
initiation of IFN-a treatment or biochemotherapy was significantly
correlated to therapeutic response (Ha ˚kansson et al, 1996, 2001).
During IFN-a treatment, these lymphocytes were also shown to
migrate from the stromal areas surrounding the tumour nodules
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Figure 5 Kaplan–Meier analysis for TTP and OS on patients whose tumour showed significant levels, that is 425% of the tumour cells, of MHC II
expression.
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Figure 6 Kaplan–Meier analysis for TTP and OS on patients whose tumour showed different levels of B7.1 and B7.2 expression.
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redistribution of the lymphocytes regressive tumour changes
appeared. These findings are highly suggestive of an antitumour
activity exerted by CD4+ lymphocytes. A prerequisite for an
antitumour activity by these lymphocytes is, however, that the
tumour cells express MHC II (Zennadi et al, 2001).
It is conceivable that MHC II expression by the tumour cells is a
result of inflammatory regression of the tumour following
treatment. In this inflammatory milieu IFNg most likely will be
produced, resulting in the local induction of MHC II expression by
tumour cells, which would be in accordance with the data
presented in this paper. However, it remains arguable whether
the MHC II-positive tumour cells have a local stimulatory effect on
tumour infiltrating CD4+ cells or a suppressive effect or no effect
at all. In vitro studies have shown that binding of CD4+ cells to
MHC II in the absence of B7 molecules can lead to an immune
suppressed or anergic state of the CD4+ cell (Becker et al, 1993).
MHC II expression by nonprofessional APC is also considered a
negative feedback mechanism to maintain peripheral tolerance
(Marelli-Berg and Lechler, 1999). In this light, MHC II expression
by tumour cells could represent a negative factor in the
immunological control of cancer and may be an explanation for
the finding that MHC II expression in primary melanoma and
locoregional melanoma metastases is associated with an unfavour-
able prognosis (van Duinen et al, 1988; Ruiter et al, 1991). In the
present study, however, MHC II expression by tumour cells in
metastatic lesions from biochemotherapy-treated patients was
associated with longer TTP and OS. As shown in this study, in the
majority of MHC II-positive lesions also expression of B7.1 and/or
B7.2 by tumour cells was found. Possibly, this coexpression of
MHC II and B7 increases the immunogenicity of the tumour as has
been demonstrated in in vitro studies and mouse tumour models
(Becker et al, 1993; Chen et al, 1994; Baskar et al, 1996; Pulaski and
Ostrand-Rosenberg, 1998; Ostrand-Rosenberg et al, 1999). Surpris-
ingly, however, no significant correlation between B7.1 or B7.2
expression in itself and regression of the tumour, TTP or OS was
found. In any case, the question as to why in most patients the
immunological control of tumour growth is only partial still
remains. In this respect the results presented in this paper could
also be seen in a different light. As mentioned earlier, it is
conceivable that MHC II expression by the tumour cells, as
frequently observed in the metastatic lesions of biochemotherapy-
treated patients, is a result of the local inflammatory milieu
following immune reactivity against the tumour, thus indicating
the successful (systemic) induction of an antitumour immune
response, and hence associated with regressive changes in the
lesions and longer TTP and OS of the patients. Locally, the
expression of MHC II on tumour cells may still have a detrimental
effect on the T-cell response by causing local downregulation or
anergy of the T cells. Possibly, this might influence the expression
of CD28 and the x-chain, as these molecules were found to be
downregulated, in particular, in regressive tumour areas during
IFN-a treatment or biochemotherapy (Ha ˚kansson et al, 1999). In
this respect, data on the heterogeneous effects of B7 molecules on
T-cell modulation may also be relevant (Martin-Fontecha et al,
1996; Kosmaczewska et al, 2001). Both B7.1 and B7.2 bind to CD28
and CTLA4, but with different affinity and possibly resulting in
different signalling pathways (Martin-Fontecha et al, 1996;
Kosmaczewska et al, 2001). For instance, while CD28 triggering
has been shown to be crucial in T-cell activation, CTLA4 triggering
appears to be mainly associated with downregulation or inhibition
of T-cell responses (Greenfield et al, 1998; Kosmaczewska
et al, 2001). Also the role of other costimulatory molecules
may be of significance. Although B7 molecules are often seen as
crucial factors for costimulation, some reports have also
indicated that other costimulatory molecules, for example,
ICAM-1, may be sufficient for efficient T-cell activation (Robinson
and Delvig, 2002).
Other recent findings, however, may also cast a different light on
the immunological significance of MHC II expression by
tumour cells. The relevance of tumour cells as APC for CD4+
cells appears to be dependent on the coexpression of MHC II
and accessory molecules such as the invariant chain (Ii) and
HLA-DM (Armstrong et al, 1997; Brocke et al, 2002), each of
which are under the primary control of CIITA, the Class II
transactivator. Normally MHC II is expressed in concert with
these accessory molecules and mainly exogenous antigens are
presented (Masternak et al, 2000; Robinson and Delvig, 2002).
In this situation, tumour cells appear to be poor immunogens
(Armstrong et al, 1997; Blanck, 1999). However, when MHC II is
expressed without coexpression of Ii and HLA-DM, such as in
MHC II-transduced or -transfected tumour cells, they may
become potent immunogens by presenting endogenous antigens,
provided that B7 expression is induced following MHC II
engagement or expressed through cotransfection or cotransduc-
tion of the B7 gene(s) (Baskar et al, 1996; Armstrong et al, 1997).
MHC II-expressing tumour cells in tumours may thus be poor
APC or even immunologically inert to CD4+ cells. The
question then remains as to why in certain cases MHC II
expression by tumour cells is associated with a poor prognosis
in melanoma and why in other cases, as in the present study,
MHC II expression is positively correlated with clinical
response parameters. As mentioned earlier, expression of MHC
II and its accessory molecules is primarily controlled by CIITA.
For CIITA expression itself, four different promoters have been
identified (Muhlethaler-Mottet et al, 1997). Each promoter is
functional in different cell types and/or under different physiolo-
gical conditions (Muhlethaler-Mottet et al, 1997; van der Stoep
et al, 2002). Promoters I and III direct specific constitutive
expression of CIITA in dendritic cells and B cells, respectively,
while promoter IV is inducible by IFN-g and is responsible for the
IFN-g-inducible expression of CIITA and thus MHC II in
nonprofessional APC. The function of promoter II is still
unknown. In melanoma cell lines, for a nonprofessional APC,
the uncommon feature of constitutive expression of MHC II has
frequently been described (Nistico et al, 1990; Goodwin et al,
2001). Deffrennes et al (2001) recently found that in a number of
melanoma cell lines, constitutive expression of MHC II was
associated with constitutive expression of CIITA, which was,
against their expectations, initiated from promoter III, and
propose that this feature is not a random event but is linked to
the neoplastic state of melanoma cells. These findings open up the
possibility that MHC II expression by tumour cells may be of
limited immunological significance and represent an epipheno-
menon of other biological processes. If MHC II expression by
melanoma cells, as often seen in primary melanomas and
locoregional metastases, is because of constitutive expression of
CIITA initiated from promoter III as a consequence of dediffer-
entiation of the tumour cells (Deffrennes et al, 2001; van der Stoep
et al, 2002), the poor prognosis for patients with MHC II-positive
tumours may be a result of the more malignant phenotype of the
tumour than any effect of the MHC II expression in itself. In
contrast, in cases where MHC II expression by tumour cells is
because of IFN-g-induced expression of CIITA, the expression of
MHC by tumour cells may be linked to an ongoing local
antitumour immune response with local IFN-g production, and
would therefore be positively correlated to clinical response
parameters as already suggested above. Whether the MHC II
expression itself is then of immunological significance remains to
be established.
In conclusion, MHC II expression in metastatic melanoma is
relevant as a biomarker for response and/or prognosis; its
immunological significance, however, remains to be established.
Further elucidation of the apparent complex machinery regulating
expression of MHC II and its accessory molecules and expression
of costimulatory molecules is warranted.
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